PTC Therapeutics, Inc. (PTCT) income statement
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.23−0.13 (-0.22%)
Close on Nov 18, 2026Market cap $5.03BP/E –Yield –
PTC Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 12.8%
- Net margin
- -9.2%
- Return on equity, FY2025
- -104.7%
Financial strength
- Current ratio
- 3.27
- Debt to equity
- -2.80
- Debt to assets
- 16.7%
- Cash to current liabilities
- 65.6%
Valuation
- P/E ratio
- –
- Price to sales
- 4.35
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?